We are live on ! Find out more
DA

DCF Advisers Portfolio holdings

AUM $375M
1-Year Est. Return 72.65%
This Fund
S&P 500
This Quarter Est. Return
+5.2%
1 Year Est. Return
+72.65%
3 Year Est. Return
+156.29%
5 Year Est. Return
+218.72%
10 Year Est. Return
AUM
$250M
AUM Growth
+$56M
Cap. Flow
+$44.7M
Cap. Flow %
17.87%
Top 10 Hldgs %
51.39%
Holding
108
New
15
Increased
21
Reduced
34
Closed
11

Top Buys

Rank Stock Value
1
AMZN icon
Amazon
AMZN
+$3.19M
2
MU icon
Micron Technology
MU
+$1.73M
3
C icon
Citigroup
C
+$1.45M
4
URNM icon
Sprott Uranium Miners ETF
URNM
+$1.1M
5
AMGN icon
Amgen
AMGN
+$818K

Sector Composition

Rank Sector Weight
1 Healthcare 26.92%
2 Technology 16.18%
3 Communication Services 7.16%
4 Consumer Discretionary 6.33%
5 Financials 3.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
JFR icon
101
Nuveen Floating Rate Income Fund
JFR
$1.24B
-29,500
Closed -$255K
JNJ icon
102
Johnson & Johnson
JNJ
$618B
-3,000
Closed -$438K
SHOP icon
103
CALL
Shopify
SHOP
$152B
-4,000
Closed -$264K
SHOP icon
104
Shopify
SHOP
$152B
-4,000
Closed -$264K
SNOW icon
105
Snowflake
SNOW
$102B
-3,250
Closed -$439K
ZBH icon
106
CALL
Zimmer Biomet
ZBH
$18.2B
-2,000
Closed -$217K

Similar funds

DCF Advisers's Q3 2024 Portfolio in Review

As of Q3 2024, DCF Advisers held 108 positions worth $250M, up 29% from $194M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

DCF Advisers deployed $44.7M of net new capital in Q3 2024, opening 15 new positions and adding to 21 existing holdings. Its largest new stake was NewAmsterdam Pharma: 34,000 shares worth $564K.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 34% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $2.95M trimmed.

  • DCF Advisers's largest Q3 2024 buy was NewAmsterdam Pharma: 34,000 shares worth $564K.
  • DCF Advisers added most to Amazon in Q3 2024, an estimated $3.19M increase.
  • DCF Advisers's biggest Q3 2024 reduction was Regeneron Pharmaceuticals, cutting an estimated $2.95M.
  • DCF Advisers fully exited Snowflake in Q3 2024, selling an estimated $439K.
  • DCF Advisers's ten largest holdings make up 51% of its $250M portfolio in Q3 2024.
  • DCF Advisers opened 15 new positions and closed 11 in Q3 2024.
  • DCF Advisers's portfolio value rose 29% quarter-over-quarter to $250M.

Based on DCF Advisers's 13F filing for Q3 2024, filed 13 Nov 2024.